Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions.
Adverse drug reactions adverse drug reaction (ADR) occur in approximately 17% of patients. Avoiding ADR is thus mandatory from both an ethical and an economic point of view. Whereas, pharmacogenetics changes of the pharmacokinetics may contribute to the explanation of some type A reactions, strong relationships of genetic markers has also been shown for drug hypersensitivity belonging to type B reactions. We present the classifications of ADR, discuss genetic influences and focus on delayed-onset hypersensitivity reactions, i.e., drug-induced liver injury, drug-induced agranulocytosis, and severe cutaneous ADR. A guidance how to read and interpret the contingency table is provided as well as an algorithm whether and how a test for a pharmacogenetic biomarker should be conducted.
Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein Kiel, Germany.
Ruwen
R
Böhm
Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein Kiel, Germany.
Ingolf
I
Cascorbi
adverse drug reactions (ADRs); drug hypersensitivity reactions; drug-induced agranulocytosis (DIA); drug-induced liver injury (DILI); drug-induced severe cutaneous adverse reactions (SCARs)